

Proposed Acquisition of Movetis NV

Supplement to Press Release

August 3, 2010



Our purpose

We enable people with life-altering conditions to lead better lives

Movetis

- GI specialty company created in 2006
 - J&J spin off of the Janssen GI small molecule pipeline
 - Janssen were the foremost experts on motility disorders in the industry
 - Based in Turnhout, Belgium
- RESOLOR® an attractive, recently launched product
 - Unique pro-kinetic Mechanism of Action (MOA): selective 5-HT₄ agonist
 - NCE with Composition of Matter patent protection extended through 2020
 - Indicated for symptomatic treatment of women with chronic constipation in whom laxatives fail to provide adequate relief
- Two compounds in early clinical development
 - M0002, vasopressin for ascites
 - M0003, selective 5HT4 agonist for refractory GERD (Gastroesophageal Reflux Disease)
- Small molecule GI library

Terms of the Offer

- €19 per share in cash for all of the issued shares
 - €428m Equity Value
 - As at March 31, 2010, the enterprise value of Movetis (less cash) would be €328 million.
- It is anticipated that the offer to Movetis's shareholders will open for acceptance in early September 2010
 - Contingent upon the fulfillment of certain customary conditions, including receipt of acceptances in respect of at least 90% of the shares that are the subject of the offer and that Movetis does not suffer a material adverse change before the results of the offer are published
- Movetis's Board unanimously supports the transaction and will recommend acceptance of the offer to its shareholders
- Institutional shareholders, holding in aggregate 38.9% of Movetis' issued share capital, have unconditionally agreed to accept the offer in respect of their own shares

For more information about



please see Movetis investor presentation at the link below

http://www.movetis.com/files/investors/Movetis%20IR%20presentation%2031%20May%202010_0.pdf

Competitive Landscape

Competitor	MOA	Indications	Status
AMITIZA® (lubiprostone, Sucampo)	Selective chloride channel activator	IBS-C & Chronic constipation	<ul style="list-style-type: none"> • Partnered with Takeda in US & Japan • MAA withdrawn in EU
Linaclotide (Ironwood)	GC-C agonist; increases chloride and bicarbonate secretion in intestinal lumen	<ul style="list-style-type: none"> • Phase 3 data in CIC complete • Phase 3 IBS-C ongoing 	<ul style="list-style-type: none"> • Partnered with Almirall in EU, Astellas in Japan and Forest in US
AR7505 (Aryx)	5-HT ₄ agonist	Phase 2 data (CIC)	<ul style="list-style-type: none"> • P&G returned rights in 2007 • Worldwide
TD5108 (Theravance)	5-HT ₄ agonist	Phase 2 data (CIC)	Worldwide

Strong strategic fit with Shire's growing core GI business

Shire Criteria	Comment
Symptomatic disease	Chronic constipation is highly symptomatic and can be extremely painful with debilitating symptoms
High unmet need	40%* of patients with chronic constipation not satisfied with current treatment Substantial need for effective, well tolerated drug
Specialist focus	RESOLOR promotion to be focused on gastroenterologists General practitioners expected to adopt later in product life
Commercial Value	Shire estimates potential peak sales of over €300 million
#1/#2Market position	First-to-market selective 5-HT ₄ agonist (unselective ZELNORM® (US) and PROPULSID® withdrawn due to cardiovascular side effects) Expected to be only pro-motility agent on EU market for chronic constipation for the next 5 years
Strong IP	RESOLOR a new chemical entity (NCE) with composition of matter patent extending through 2020
Geographic expansion	RESOLOR rights for European Economic Area (EEA) Pipeline products in early clinical development: M0002 worldwide rights, M0003 rights for Europe and North America